28 jun: Når lav risiko giver højt afkast
17 jul: Test
12-07-2012 21:34:00

Mexico's BBVA Bancomer Places $1 Billion in 10-Year Notes

Relateret indhold

MEXICO CITY--The Mexican unit of Spain's Banco Bilbao Vizcaya Argentaria SA (BBVA, BBVA.MC) said Thursday it has placed $1 billion in 10-year notes that yield 6.75%.

BBVA Bancomer, Mexico's largest bank, said the offer was 3.5 times oversubscribed and that investors in Asia, Europe, Latin America and the U.S. participated in the deal.

The notes priced at the bottom of the price range floated in the market, the bank said, without giving the price.

The offering was of lower tier II bonds, meaning the debt sits low in a bank's capital structure to serve as a cushion of capital for senior bondholders. This makes them riskier investments, but they yield more to compensate investors.

Nearly $23 billion of subordinated bonds have been sold by financial institutions so far this year, outpacing the $18.3 billion sold in 2011, according to research company Dealogic. The continual drop in interest rates has made it more attractive for banks to bolster their capital through issuing subordinated bonds.

Foreign institutions that need dollar-based funding have accounted for 60% of 2012 issuance, according to Dealogic, whereas U.S. banks tend to be flush with deposits.

BBVA Bancomer said the bond sale will help it continue to extend credit, thus further contributing to Mexico's economic growth.

The bank expanded its credit portfolio in Mexico last year by 9% to 609.7 billion pesos ($45.33 billion).

BBVA Bancomer is a major source of profit for its Spanish parent. In the first quarter, Mexico accounted for 430 million euros ($527 million) of BBVA's EUR1.01 billion net profit, while Spain only supplied EUR229 million.

-Patrick McGee contributed to this article.

Write to Amy Guthrie at amy.guthrie@dowjones.com

(END) Dow Jones Newswires

July 12, 2012 15:34 ET (19:34 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Novo-rival spår effekt af ugentligt GLP-1 på linje med Ozempics

13-12-2017 13:30:09
Novo Nordisks store franske rival Sanofi forudser, at dens ugentlige GLP-1-analog, Efpeglenatid, har en effekt på langtidsblodsukkeret, der er på linje Novos nye ugentlige diabetes 2-middel Ozempic, som tilhører samme lægemiddelklasse.Det fremgår af en præsentation under et analytikerarrangement onsdag, hvor Sanofi fremlægger sin forsknings- og udviklingsstrategi for de kommende år.Sanofi indledte..

Novo-rival er på vej med nye studier i fedme og leversygdommen NASH

13-12-2017 09:56:25
Novo Nordisks store franske rival, Sanofi, vil ligesom Novo i de kommende år også fokusere på udviklingen af fedmemedicin og medicin til behandling af leversygdommen, NASH.Det fremgår af en pressemeddelelse i forbindelse med et analytikerarrangement onsdag, hvor Sanofi vil præsentere sin forsknings- og udviklingsstrategi for de kommende år.Sanofis udviklingsindsats inden for forretningsområdet, di..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas får sin største ordre nogensinde i Indien - NY
2
Aktier/tendens: Genmab og Vestas fortsætter i fokus
3
Vestas rykker nærmere kæmpekontrakter i New Mexico og Texas
4
Vestas ejer mere end 5 pct. egne aktier efter opkøb
5
KORR: TK Development-formand køber aktier for 1,9 mio. kr.

Relaterede aktiekurser

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
13. december 2017 17:52:26
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20171124.1 - EUROWEB3 - 2017-12-13 17:52:26 - 2017-12-13 17:52:26 - 1 - Website: OKAY